secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001171843-24-002765
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cassava Sciences Q1 net income $25M; Phase 3 Alzheimer's trials on track with >1,900 patients
--------------------------------------------------------------------------------

- Net income of $25.0M vs net loss $24.3M in Q1 2023; non-cash warrant gain drove the swing.
- $126.3M in gross proceeds from warrant exercise; cash & equivalents $124.2M, no debt as of March 31.
- Over 1,900 patients randomized across two Phase 3 simufilam trials; >735 patients have completed.
- Top-line data for 52-week RETHINK-ALZ expected year-end 2024; 76-week REFOCUS-ALZ data mid-2025.
- Q1 R&D spend $16.2M, down from $22.1M YoY; H1 2024 operating cash burn guided at $35-45M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324002765/0001171843-24-002765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184324002765/f8k_051024.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer